About 12% of Americans are currently taking a GLP-1 receptor agonist, and the number keeps climbing. Most of them are focused on the number going down on the scale. Far fewer are thinking about what’s happening to their skeleton in the process.
Bone density doesn’t make headlines the way blood sugar and waist circumference do. But a quiet pattern is emerging in the clinical data: a 2026 JCEM study found that patients using semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) experienced significantly greater annualized total hip bone loss than matched controls, particularly among patients taking these drugs for weight loss without type 2 diabetes as an underlying condition. The bone loss isn’t dramatic in isolation. What makes it worth close attention is the timing.
GLP-1 drugs produce large, fast results. That speed is part of what makes them so popular and, for bones, more complicated. Type 2 diabetes and weight loss are each independently associated with skeletal health – and GLP-1 medications are often used by people who use them for both type 2 diabetes and weight loss. Researchers now have a clearer picture of who’s most vulnerable and what actually works to protect bone while the weight comes off.
How GLP-1 Drugs and GLP-1 Bone Density Are Connected
GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, interact with the body’s bone metabolism in complex ways. These medications act on receptors in both osteoblasts (the cells that build bone) and osteoclasts (the cells that break bone down), potentially tipping the balance between bone formation and resorption.
The most rigorous bone-specific human data comes from a 2024 randomized controlled trial published in eClinicalMedicine. Researchers enrolled 64 adults with elevated fracture risk and randomly assigned them to once-weekly semaglutide or a placebo for 52 weeks. The semaglutide group saw hip bone mineral density fall by 2.6% and lumbar spine density by 2.1% compared to placebo. Bone resorption markers – chemicals that signal bone breakdown – increased, while bone formation markers did not compensate.
A 2.6% drop at the hip in a single year sits against a meaningful baseline: postmenopausal women lose on average 1 to 2% of hip bone density per year. A year on semaglutide can therefore compress two to three years of normal age-related bone decline into twelve months, and for a postmenopausal woman, that stacking effect is the core concern.
The mechanism behind this isn’t unique to GLP-1 drugs. Contributing factors to weight-loss-driven bone loss include reduced mechanical loading, hormonal alterations, nutritional deficiencies, and disruptions in metabolic signalling – all of which can occur when body weight drops quickly regardless of how that weight loss happened. Bone changes tend to occur when people lose at least 7% to 10% of their body weight, and GLP-1 medications routinely clear that threshold. GLP-1 drugs often produce weight loss of 15 to 20% of total body weight, meaning virtually everyone who responds well to the drug crosses into the bone-loss risk zone.
“Bone is a mechanically sensitive tissue—all that really means is that it responds to the load that’s placed on it, and body weight is a form of load,” says Sarah J. Wherry, PhD, an Assistant Professor at the University of Colorado School of Medicine, “So, when you ‘off’ load, you’re going to remove some of that stress and strain on the skeleton and it’s going to adapt.”
Research findings suggest that GLP-1 receptor agonist effects on bone may differ by diabetes status, with weight loss driving bone loss more prominently in patients without diabetes. Someone using semaglutide purely for weight loss may face a steeper skeletal cost than someone using it to manage type 2 diabetes alongside metabolic complications.
Who Faces the Highest Risk
Not everyone on a GLP-1 drug faces the same bone picture. Patients who already face elevated fracture risk deserve particular attention when building a bone health plan: postmenopausal women, adults over 65, and anyone with pre-existing osteopenia or osteoporosis.
A 2024 randomized controlled trial in eClinicalMedicine enrolled adults with elevated fracture risk, a population that skews older and female, and found lumbar spine and total hip bone mineral density both lower in the semaglutide group after 52 weeks. This is the demographic where the bone-density question becomes most clinically urgent.
A 2026 study presented at the American Academy of Orthopaedic Surgeons annual meeting added a longer-term dimension to this concern. After five years, patients taking GLP-1 receptor agonists demonstrated a significantly increased risk of osteoporosis compared to controls.
The rate of weight loss also matters independent of how much weight is ultimately lost. Larger observational data link semaglutide- and tirzepatide-associated weight loss to significant lumbar spine, femoral neck, and total hip bone mineral density declines, with total hip loss correlating to the percent of weight reduction. The faster and larger the loss, the more the skeleton is asked to adapt.
Muscle loss compounds this. The SURMOUNT-1 DXA substudy, published in Diabetes, Obesity and Metabolism in 2025, showed that tirzepatide reduced lean body mass by 10.9% over 72 weeks compared to 2.6% with placebo, with approximately 25% of total weight lost being lean mass. Muscle and bone respond to the same mechanical signals. When muscle shrinks, the load-bearing signals that tell bones to stay dense also weaken.
For an in-depth look at how these drugs affect skeletal and joint health beyond density, orthopedic surgeons weigh in on GLP-1 patients covers the clinical picture in detail.
The Data Isn’t All Negative
A 2025 meta-analysis published in Acta Diabetologica found that bone mineral density and bone turnover markers improved in people with type 2 diabetes who took GLP-1 receptor agonists, with no increase in fracture risk observed in that population. A separate 2026 study presented at the Endocrine Society’s annual meeting found that semaglutide was associated with a 15% reduction in bone fractures compared to other anti-obesity medications in patients with type 2 diabetes.
Most of the fracture reduction data comes from people with type 2 diabetes, whose bones are often more fragile and fracture-prone at baseline. For those patients, better blood sugar control and lower fall risk from improved mobility may outweigh a modest density dip.
Larger prospective studies with fracture outcomes are needed and are expected to be initiated given the clinical significance of this signal. The FDA has not yet issued specific guidance on bone density monitoring for patients on GLP-1 therapy, though its label for semaglutide notes that the drug might increase the risk of bone fractures in older adults and women.
What Helps to Protect Your Bones
A 2024 randomized clinical trial from the University of Copenhagen, published in JAMA Network Open, split 195 adults with obesity into four groups for one year: exercise only, GLP-1 medication (liraglutide) only, the combination, or placebo. The liraglutide-only group showed significant bone mineral density decreases at the hip and spine compared to the exercise group. The combination of exercise and liraglutide was the most effective weight loss strategy while also preserving bone health. Liraglutide alone reduced bone mineral density at clinically relevant sites more than exercise alone did, despite producing similar weight loss.
In that Danish trial, exercise alone fully preserved hip and spine bone density during weight loss. Resistance and weight-bearing training signal the skeleton to hold onto bone under load: weight-bearing exercises increase the mechanical load on bones, prompting the body to build and strengthen bone tissue – the precise signal that rapid weight loss tends to suppress.
Protein intake is the second lever. Structured resistance training combined with higher protein intake of more than 1.2 grams per kilogram of body weight per day, distributed evenly across meals, can mitigate lean soft tissue loss. Higher protein intake is linked to greater bone density, with women seeing gains at intakes of up to about 60 grams of protein per day.
Calcium and vitamin D have been shown to reduce bone loss and fracture risk, particularly in individuals with deficiencies. Research published in 2026 confirmed this finding across general populations, and for people already eating less food due to appetite suppression from GLP-1 medications, these micronutrients are among the first to fall short without intentional supplementation.
However, bone density and the risk of losing it are influenced by factors including genetics, age, and the habits you develop throughout your life. Wherry said to Women’s Health, “It’s those actions that you took earlier in your life that are going to increase your risk for osteoporosis later.”
Further highlighting this to Women’s Health, Lauren Manaker, RDN, CPT, a registered dietitian-nutritionist, says that someone who has consistently followed a nutrient-rich diet with plenty of calcium, vitamin D, and magnesium over the course of 40 years may have a different bone health outlook than someone who has rarely prioritized a nutritious diet.
Read More: Warning Issued Over Little-known Side Effect to Anyone Who Uses Mounjaro, Ozempic and Wegovy
What to Do Now
The bone findings from current research are not a reason to stop GLP-1 medications or to avoid them. They are a reason to build a bone health plan before and during treatment, particularly for postmenopausal women, adults over 65, and anyone with pre-existing osteopenia or osteoporosis.
Start with a baseline DEXA scan – a low-radiation imaging test that measures bone mineral density – before or shortly after starting a GLP-1 drug. Resistance training, adequate protein, calcium and vitamin D supplementation, and baseline DEXA screening are not extras. For patients on GLP-1 therapy, they represent the standard of care for safe, sustainable weight loss.
For postmenopausal women, the math is particularly clear. Losing 15 to 20% of body weight on a GLP-1 drug in under a year, without any protective measures in place, can accelerate bone decline at exactly the stage of life when preserving skeletal capital matters most. Hip fractures in older women carry serious consequences for independence and long-term health. Resistance training three times a week, a protein target above 1.2 g/kg/day, and a daily calcium and vitamin D supplement are, based on current evidence, the most effective protective interventions available while larger long-term trials catch up to the millions of people already on these drugs.
The FDA has not yet issued specific guidance on bone density monitoring for GLP-1 therapy, but clinical societies in endocrinology and orthopedics are expected to address this in upcoming practice guidelines. The practical recommendation from the available research is clear: treat bone protection as part of the weight-loss plan from day one, not something to consider if problems emerge later.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.